GEMCOVAC®-OM
Gennova’s Omicron mRNA booster, GEMCOVAC®- OM, which is stable at 2-8°C,
has received the Emergency Use Authorization (EUA)
Gennova’s Omicron mRNA booster, GEMCOVAC®- OM, which is stable at 2-8°C,
has received the Emergency Use Authorization (EUA)
Developed to address the problems in the earlier approved mRNA vaccines.
The mRNA development platform has the potential to develop rapidly.
GEMCOVAC® mRNA vaccine is stable at 2–8 °C and can be considered superior in terms of deployability in India and other developing nations (especially LMICs) compared to other approved mRNA vaccines.
Gennova's Omicron Specific mRNA booster vaccine.
Gennova's mRNA vaccine prototype for COVID-19
CIN – U24231PN2001PLC016253
Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C.,
Hinjawadi, Pune – 411057, Maharashtra, INDIA
BTS – 2 Building, Chrysalis Enclave, Block – 2, Plot -2,
TCG International Biotech Park,
Phase II, MIDC, Hinjawadi, Pune – 411 057,
Maharashtra – India
Block -1, Plot P1 & P2, ITBT Park, Phase II, MIDC,
Hinjawadi, Pune – 411 057, Maharashtra, India.
Copyright © 2006 - 2025 Gennova Biopharmaceuticals Limited - All Rights Reserved.